Of 281 NSCLC patients, 125 patients had concurrent high FABP3 and FABP4 protein expression in tumor (FABP3+/FABP4+), 86 patients had either high FABP3 or high FABP4 protein expression in tumor (FABP3+/FABP4- or FABP3-/FABP4+), and 70 patients had no high protein expression of FABP3 and FABP4 (FABP3-/FABP4-). The gene discussed is FABP4; the disease is non-small cell lung carcinoma.